Sun Pharma, Glenmark get US FDA nod for Riluzole 50mg tablets
As per the United States Food and Drug Administration (USFDA) web site, the approvals were given for generic Riluzole oral tablets in the strength of 50 mg.
New Delhi: India's Sun Pharmaceutical Industries and Glenmark Generics have got approval from US health regulator to sell generic versions of nervous system disorder treatment drug Riluzole.
As per the United States Food and Drug Administration (USFDA) web site, the approvals were given for generic Riluzole oral tablets in the strength of 50 mg.
[caption id="attachment_895749" align="alignleft" width="380"]
Reuters[/caption]
Riluzole is indicated for treatment of amyotrophic lateral sclerosis. As per IMS Health sales data for the 12 month period ended March 2013, Riluzole had garnered sales of USD 64 million in the US market.
Glenmark Generics is a subsidiary of Glenmark Pharma and focuses on developing, manufacturing, selling and the distribution of generics through wholesalers, retailers and pharmacy chains.
More from BusinessShares of Sun Pharmaceutical Industries and Glenmark Pharmaceuticals today respectively closed at Rs 949.85 and Rs 542.85 per scrip on BSE, down 1.85 and 1.90 per cent from their previous close.
PTI
US jobless claims fall to 187,000, signalling resilient labour market ahead of Fed meeting
NDTA asks Connaught Place shops, offices and restaurants to close by 6:30 pm today
EU slaps Google with $1 billion antitrust fine over Play Store and Search practices
Brent crude flirts with $100, reigniting inflation and forex concerns for India
Can a record May offset a shrunk international schedule and help IndiGo turn a profit?